Chart-style summary of Soleus Capital Management, L.P.'s 13F portfolio changes for the quarter ending 2026-03-31, showing new positions, increases, and exits across healthcare and biotech stocks.

Soleus Capital Management, L.P.: 13F Portfolio Moves Tracked Quarterly

by

Soleus Capital Management, L.P. is a healthcare-focused institutional investor whose equity holdings are disclosed each quarter through SEC Form 13F filings. This profile tracks those disclosures over time, giving a running record of the fund’s reported buys, sells, and position size changes as new 13F data becomes available. Because 13F filings only capture a quarterly snapshot of holdings rather than individual trade dates, all moves below are described as occurring during the quarter ending 2026-03-31, not on any specific day.

New positions and notable increases

During the quarter ending 2026-03-31, Soleus Capital Management, L.P. opened three new positions: Indivior Pharmaceuticals Inc (INDV) worth $38,831,520, Progyny Inc (PGNY) worth $35,097,660, and Merck & Co Inc (MRK) worth $24,418,870, alongside a new stake in Icon PLC (ICLR) worth $21,246,720. The fund also added meaningfully to several existing holdings. Insulet Corp (PODD) rose 177%, from $42,636,000 to $118,035,000, while United Therapeutics Corp Del (UTHR) increased 280%, from $29,235,000 to $110,998,147. Vericel Corp (VCEL) grew 198%, from $27,511,640 to $82,003,871, and Geron Corp (GERN) climbed 101%, from $30,742,800 to $61,847,902. Other increases included Edgewise Therapeutics Inc (EWTX) up 102% to $45,672,323, TG Therapeutics Inc (TGTX) up 43% to $133,853,977, Alkermes PLC (ALKS) up 88% to $69,689,751, ANI Pharmaceuticals Inc (ANIP) up 64% to $63,076,687, and Krystal Biotech Inc (KRYS) up 28%, from $232,008,686 to $297,865,434, remaining among the fund’s largest reported positions.

Exits and reductions

The fund exited several positions entirely during the quarter ending 2026-03-31. This included Spdr Series Trust, previously worth $353,597,000, Amicus Therapeutics Inc, previously worth $74,151,724, GSK PLC (GSK) at $31,336,560, Rapt Therapeutics Inc at $25,876,680, Neurocrine Biosciences Inc (NBIX) at $24,959,527, and Teleflex Incorporated (TFX) at $23,187,600. Argenx SE (ARGX) was not fully exited but was cut sharply, down 90% from $26,679,980 to $2,555,875.

Together, these disclosures point to a quarter in which Soleus Capital Management, L.P. leaned further into several existing healthcare and biotech names while stepping away from a large index-fund holding and a handful of smaller positions. As with any 13F-based snapshot, the filings show reported holdings as of quarter end rather than the reasoning behind each move. Check back after the next filing period for updated portfolio changes from Soleus Capital Management, L.P.

Related ticker coverage

Source: SEC Form 13F filings. This page updates every quarter.

Leave a Comment